HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guttman, M. Articles by Naylor, C. D. Search for Related Content PubMed PubMed Citation Articles by Guttman, M. Articles by Naylor, C. D. Related Collections All Health Services Research Parkinson's disease/Parkinsonism Cohort studies

Parkinsonism in Ontario

Increased mortality compared with controls in a large cohort study

From the Division of Neurology (Dr. Guttman), Department of Medicine, and Dean’s Office, Faculty of Medicine (Dr. Naylor), University of Toronto, and Institute for Clinical Evaluative Sciences (P.M. Slaughter, M.-E. Theriault, and D.P. DeBoer), Toronto, Ontario, Canada.

Address correspondence and reprint requests to Dr. M. Guttman, 377 Church St. #407, Markham, Ontario, Canada, L6B 1A1; e-mail: mguttman{at}idirect.com

Background: PD was associated with increased mortality before levodopa therapy became available. There have been conflicting reports of PD mortality in the modern era.

Objective: To assess current mortality rates in a large unselected population receiving treatment for parkinsonism (PKM) followed for up to 6 years.

Methods: Cases were identified using linked administrative databases, including physician service and prescription drug claims, generated in Ontario’s universal health insurance system. Control subjects were identified from the provincial registry of citizens and age and sex matched to cases. Comparative mortality was evaluated over the 6-year period of the study (1993/94 to 1998/99). The sensitivity of the findings was tested with differing case definitions.

Results: In 1993, 15,304 patients with PKM were identified and were age and sex matched to 30,608 control subjects (1:2 ratio). Over the study period, 50.8% (7,779) of the cases with PKM died compared with 29.1% (8,899) of the control subjects. The cases with PKM had an overall mortality odds ratio of 2.5 (95% CI: 2.4, 2.6) compared with the control group. Results were consistent whether cases were defined by physician diagnosis, use of anti-PD drugs, or both criteria.

Conclusion: Despite modern drug therapy, PKM continues to confer a sharply increased mortality on unselected patients followed for several years.

This article has been cited by other articles:

				J. A. Driver, T. Kurth, J. E. Buring, J. M. Gaziano, and G. Logroscino Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study Neurology, April 15, 2008; 70(16_Part_2): 1423 - 1430. [Abstract] [Full Text] [PDF]

				L. S Ishihara, A. Cheesbrough, C. Brayne, and A. Schrag Estimated life expectancy of Parkinson's patients compared with the UK population J. Neurol. Neurosurg. Psychiatry, December 1, 2007; 78(12): 1304 - 1309. [Abstract] [Full Text] [PDF]

				L. M. L. de Lau, C. M. A. Schipper, A. Hofman, P. J. Koudstaal, and M. M. B. Breteler Prognosis of Parkinson Disease: Risk of Dementia and Mortality: The Rotterdam Study Arch Neurol, August 1, 2005; 62(8): 1265 - 1269. [Abstract] [Full Text] [PDF]

				M. Guttman, S. J. Kish, and Y. Furukawa Current concepts in the diagnosis and management of Parkinson's disease Can. Med. Assoc. J., February 4, 2003; 168(3): 293 - 301. [Abstract] [Full Text] [PDF]

				G. Levy, M.-X. Tang, E.D. Louis, L.J. Cote, B. Alfaro, H. Mejia, Y. Stern, and K. Marder The association of incident dementia with mortality in PD Neurology, December 10, 2002; 59(11): 1708 - 1713. [Abstract] [Full Text] [PDF]